<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396106</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-001</org_study_id>
    <nct_id>NCT04396106</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527
      in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor
      outcomes (such as obesity (BMI&gt;30), hypertension, diabetes or asthma). Eligible subjects will
      be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be
      administered orally for 5 days. Local supportive standard of care (SOC) will be allowed for
      all subjects. Efficacy and safety observations will be compared for treatment with active
      AT-527 tablets + SOC vs. placebo tablets + SOC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions (active vs. placebo) of subjects with progressive respiratory insufficiency.</measure>
    <time_frame>Day 14</time_frame>
    <description>Progressive respiratory insufficiency defined as a ≥ 2-tier increase in respiratory support methods required to maintain satisfactory oxygenation (SpO2 ≥ 93%), using the 6-tier hierarchical scale of respiratory support methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical recovery</measure>
    <time_frame>Day 14</time_frame>
    <description>Clinical recovery defined as time from randomization to disease resolution status on an 8 point Clinical Status scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions (active vs. placebo) of subjects with respiratory failure or death</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>AT-527 + SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>One or two 550 mg tablet(s) of AT-527 administered on Day 1 followed by 1 tablet every ~12 hours (twice a day) + SOC for a total of 5 days</description>
    <arm_group_label>AT-527 + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One or two placebo tablet(s) administered on Day 1 followed by 1 tablet every ~12 hours (twice a day) + SOC for a total of 5 days</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Hospitalized or in a hospital-affiliated confinement facility

          -  SARS-CoV-2 positive

          -  Initial COVID-19 symptom onset within 5 days prior to Screening

          -  SpO2 ≥ 93% on room air or requires ≤ 2L/min oxygen by nasal cannula or mask to
             maintain SpO2 ≥ 93%

          -  Must also have a history of at least one of the following known risk factors for poor
             outcomes: obesity (BMI&gt;30), hypertension, diabetes or asthma.

        Key Exclusion Criteria:

          -  Severe or critical COVID-19 illness: RR ≥30, HR ≥125, SpO2 &lt;93% on room air or
             requires &gt;2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥93%, systolic blood
             pressure &lt; 90 mm Hg, diastolic blood pressure &lt; 60 mm Hg or PaO2/FiO2 &lt;300

          -  Requires mechanical ventilation

          -  Lobar or segmental consolidation on chest imaging.

          -  Treatment with other drugs thought to possibly have activity against SARS-CoV-2

          -  ALT or AST &gt; 5 x upper limit of normal (ULN)

          -  Female subject is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>888-481-1607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

